# Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment

> **NCT07460206** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Gruppo Oncologico Italiano di Ricerca Clinica** · enrollment: 108 (estimated)

## Conditions studied

- ccRCC

## Interventions

- **DRUG:** Pembrolizumab 200 mg Q3W
- **DRUG:** Lenvatinib 20mg QD

## Key facts

- **NCT ID:** NCT07460206
- **Lead sponsor:** Gruppo Oncologico Italiano di Ricerca Clinica
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2031-08
- **Final completion:** 2031-12
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07460206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07460206, "Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07460206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*